Amgen (AMGN) Net Margin (2009 - 2026)
Amgen's quarterly Net Margin came in at 21.11% in Q1 2026, down 12.0% year-on-year from 23.99% in Q1 2025, and up 56.22% quarter-over-quarter from 13.51% in Q4 2025.
Amgen has reported Net Margin for 18 years, with the latest figure at 21.11% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin fell 12.0% year-over-year to 21.11%; the trailing twelve-month figure through Mar 2026 stood at 20.96% (up 357.0% YoY), and the FY2025 full-year result was 20.98%, up 875.0% from the prior year.
- Net Margin for Q1 2026 stood at 21.11%, up from 13.51% in the prior quarter.
- The five-year high for Net Margin was 352.07% in Q4 2022, with the low at 1.52% in Q1 2024.
- Average Net Margin over 5 years is 40.07%, with a median of 21.11% recorded in 2026.
- Year-over-year, Net Margin surged 32433 bps in 2022 and plunged 34271 bps in 2023.
- Tracing AMGN's Net Margin over 5 years: stood at 352.07% in 2022, then plunged by 97 bps to 9.36% in 2023, then declined by 26 bps to 6.9% in 2024, then surged by 96 bps to 13.51% in 2025, then soared by 56 bps to 21.11% in 2026.
- The last three Net Margin figures came in at 21.11% (Q1 2026), 13.51% (Q4 2025), and 33.65% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 37.36% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 21.76% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 4.65% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -25.84% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 21.11% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 29.04% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -0.56% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 23.32% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.11% |
| Dec 31, 2025 | 13.51% |
| Sep 30, 2025 | 33.65% |
| Jun 30, 2025 | 15.60% |
| Mar 31, 2025 | 21.23% |
| Dec 31, 2024 | 6.90% |
| Sep 30, 2024 | 33.28% |
| Jun 30, 2024 | 8.89% |
| Mar 31, 2024 | -1.52% |
| Dec 31, 2023 | 9.36% |
| Sep 30, 2023 | 25.06% |
| Jun 30, 2023 | 19.74% |
| Mar 31, 2023 | 46.54% |
| Dec 31, 2022 | 352.07% |
| Sep 30, 2022 | 32.22% |
| Jun 30, 2022 | 19.97% |
| Mar 31, 2022 | 23.66% |
| Dec 31, 2021 | 27.74% |
| Sep 30, 2021 | 28.09% |
| Jun 30, 2021 | 7.11% |
| Mar 31, 2021 | 27.89% |
| Dec 31, 2020 | 25.50% |
| Sep 30, 2020 | 31.47% |
| Jun 30, 2020 | 29.05% |
| Mar 31, 2020 | 29.62% |
| Dec 31, 2019 | 28.96% |
| Sep 30, 2019 | 36.02% |
| Jun 30, 2019 | 39.09% |
| Mar 31, 2019 | 37.68% |
| Dec 31, 2018 | 32.13% |
| Sep 30, 2018 | 33.74% |
| Jun 30, 2018 | 40.43% |
| Mar 31, 2018 | 43.25% |
| Dec 31, 2017 | -76.57% |
| Sep 30, 2017 | 37.06% |
| Jun 30, 2017 | 38.59% |
| Mar 31, 2017 | 39.83% |
| Dec 31, 2016 | 34.17% |
| Sep 30, 2016 | 36.57% |
| Jun 30, 2016 | 34.16% |
| Mar 31, 2016 | 36.27% |
| Dec 31, 2015 | 33.78% |
| Sep 30, 2015 | 33.77% |
| Jun 30, 2015 | 31.64% |
| Mar 31, 2015 | 33.30% |
| Dec 31, 2014 | 25.01% |
| Sep 30, 2014 | 25.66% |
| Jun 30, 2014 | 31.26% |
| Mar 31, 2014 | 24.63% |
| Dec 31, 2013 | 21.28% |
| Sep 30, 2013 | 29.44% |
| Jun 30, 2013 | 27.38% |
| Mar 31, 2013 | 34.55% |
| Dec 31, 2012 | 18.17% |
| Sep 30, 2012 | 26.35% |
| Jun 30, 2012 | 30.14% |
| Mar 31, 2012 | 30.35% |
| Dec 31, 2011 | 23.91% |
| Sep 30, 2011 | 11.71% |
| Jun 30, 2011 | 30.05% |
| Mar 31, 2011 | 31.09% |
| Dec 31, 2010 | 27.18% |
| Sep 30, 2010 | 32.88% |
| Jun 30, 2010 | 33.27% |
| Mar 31, 2010 | 33.08% |
| Dec 31, 2009 | 24.87% |
| Sep 30, 2009 | 37.10% |
| Jun 30, 2009 | 34.92% |
| Mar 31, 2009 | 31.47% |